Savara Inc (SVRA) - News Archive

Savara Inc., a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has recently announced the successful pricing of an underwritten offering of its common stock. The offering, totaling 26...

Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, will host a conference call and webcast on June 26, 2024, at 8:00am ET to discuss the top line results fr...

Strategic Advancements and Milestones in Savara Inc.: Analyzing Recent Initiatives and Financial Performance Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company that has established itself as a key...

In recent news, clinical stage biopharmaceutical company Savara Inc. (Nasdaq: SVRA) has made significant strides towards advancing its mission of addressing rare respiratory diseases. Two key announcements have recently...

The clinical-stage biopharmaceutical industry received the latest updates on the financial insights and business progress of Savara Inc. (Nasdaq: SVRA), a company recognized for its innovative research focused on develo...

Innovation, perseverance, and progress are the three words that take a front row in the current biopharmaceutical landscape that Savara Inc., a Nasdaq listed firm (Nasdaq: SVRA), has been actively outlining. The clinica...